82 related articles for article (PubMed ID: 15579048)
21. 15-deoxy-Δ(12,14) -prostaglandin-J2 and ciglitazone inhibit TNF-α-induced matrix metalloproteinase 13 production via the antagonism of NF-κB activation in human synovial fibroblasts.
Lin TH; Tang CH; Wu K; Fong YC; Yang RS; Fu WM
J Cell Physiol; 2011 Dec; 226(12):3242-50. PubMed ID: 21344384
[TBL] [Abstract][Full Text] [Related]
22. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists.
Alarcón de la Lastra C; Sánchez-Fidalgo S; Villegas I; Motilva V
Curr Pharm Des; 2004; 10(28):3505-24. PubMed ID: 15579048
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
Belvisi MG; Hele DJ; Birrell MA
Eur J Pharmacol; 2006 Mar; 533(1-3):101-9. PubMed ID: 16458290
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
25. PPAR-gamma in ulcerative colitis: a novel target for intervention.
Bertin B; Dubuquoy L; Colombel JF; Desreumaux P
Curr Drug Targets; 2013 Nov; 14(12):1501-7. PubMed ID: 23651165
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock.
Abdelrahman M; Sivarajah A; Thiemermann C
Cardiovasc Res; 2005 Mar; 65(4):772-81. PubMed ID: 15721857
[TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?
Luconi M; Cantini G; Serio M
Steroids; 2010; 75(8-9):585-94. PubMed ID: 19900469
[TBL] [Abstract][Full Text] [Related]
28. A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance.
Chigurupati S; Dhanaraj SA; Balakumar P
Eur J Pharmacol; 2015 May; 755():50-7. PubMed ID: 25748601
[TBL] [Abstract][Full Text] [Related]
29. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
30. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Wang M; Tafuri S
J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
[TBL] [Abstract][Full Text] [Related]
31. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
32. Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.
Ferrari SM; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Curr Med Chem; 2016; 23(7):636-49. PubMed ID: 26844838
[TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
Halabi CM; Sigmund CD
Am J Cardiovasc Drugs; 2005; 5(6):389-98. PubMed ID: 16259527
[TBL] [Abstract][Full Text] [Related]
34. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
35. The role of peroxisome proliferator-activated receptor-γ in breast cancer.
Kotta-Loizou I; Giaginis C; Theocharis S
Anticancer Agents Med Chem; 2012 Nov; 12(9):1025-44. PubMed ID: 22583414
[TBL] [Abstract][Full Text] [Related]
36. Evidence that peroxisome proliferator-activated receptor γ suppresses squamous carcinogenesis through anti-inflammatory signaling and regulation of the immune response.
Ren L; Konger RL
Mol Carcinog; 2019 Sep; 58(9):1589-1601. PubMed ID: 31111568
[TBL] [Abstract][Full Text] [Related]
37. [Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications].
Wada K; Kamisaki Y
Nihon Rinsho; 2010 Feb; 68(2):278-83. PubMed ID: 20158097
[TBL] [Abstract][Full Text] [Related]
38. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
39. [The role of PPARgamma agonists in kidney diseases].
Yokoyama Y; Doi S; Kawai T; Yorioka N
Nihon Rinsho; 2010 Feb; 68(2):317-22. PubMed ID: 20158103
[TBL] [Abstract][Full Text] [Related]
40. Function of PPARgamma and its ligands in lung cancer.
Li MY; Lee TW; Yim AP; Chen GG
Crit Rev Clin Lab Sci; 2006; 43(2):183-202. PubMed ID: 16517422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
